On Thursday, TD Cowen expressed continued confidence in Seres Therapeutics (NASDAQ:), sustaining a Purchase score on the corporate’s shares. The endorsement follows the announcement of recent information from Seres’ SER-155 examine.
The examine, which pertains to the Section 1b trial of SER-155 in sufferers present process allogeneic hematopoietic stem cell transplantation (allo-HSCT), has proven promising outcomes. In accordance with the announcement, SER-155 was well-tolerated and demonstrated preliminary indicators of efficacy.
The remedy led to a decreased incidence of bloodstream infections (BSI) with an odds ratio (OR) of 0.15 and a p-value of 0.0423. Moreover, sufferers handled with SER-155 required 11.9 fewer days of antibiotic use in comparison with those that acquired a placebo, a outcome with a p-value of 0.0494.
TD Cowen highlighted these findings as supportive proof for the development of the SER-155 program. The agency identified that this system appears to be beneath the radar, suggesting that the market might not have absolutely acknowledged its potential but.
Seres Therapeutics is targeted on the event of therapies that modulate the microbiome to enhance the lives of sufferers. The optimistic outcomes from the SER-155 examine characterize a big step ahead for the corporate’s scientific growth pipeline.
The maintained Purchase score by TD Cowen displays the agency’s optimistic outlook on Seres Therapeutics’ inventory, primarily based on the most recent scientific information. The outcomes point out a possible for SER-155 to turn into an essential remedy choice for sufferers present process allo-HSCT, lowering the chance of infections and the necessity for antibiotics.
In different latest information, Seres Therapeutics reported optimistic outcomes from its Section 1b examine of SER-155 in sufferers present process allogeneic hematopoietic stem cell transplantation. The examine revealed a big discount in bacterial bloodstream infections and systemic antibiotic use.
The corporate plans to hunt Breakthrough Remedy designation from the FDA for SER-155 as a result of excessive unmet medical want related to these infections in sufferers.
Moreover, Seres Therapeutics disclosed monetary statements for fiscal years 2023 and 2022, in step with the deliberate sale of belongings associated to its VOWST microbiome therapeutic enterprise to Nestle Well being Science.
The transaction, amounting to $155 million, is anticipated to strengthen the corporate’s monetary place and assist the event of its dwell biotherapeutic product pipeline. Regardless of a reported web lack of $32.9 million, the asset sale is projected to increase the corporate’s money runway.
Moreover, Seres Therapeutics is advancing SER-155, at present in a Section Ib examine, and getting ready SER-147 for IND readiness by the second half of 2025, concentrating on metabolic illnesses. These latest developments underscore Seres Therapeutics’ dedication to addressing illnesses with excessive unmet wants and medically weak affected person populations.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
